Saturday 17 October 2026
Export GRCE’s income statement to Excel — free account
Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
1.89
0.06
−3.08%
Follow GRCE
Grace Therapeutics, Inc. (GRCE) P/E ratio
Grace Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 197× (October 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2021 | 0.0× | — |
| Dec 2020 | 4.5× | — |
| Nov 2016 | 0.0× | — |
| Aug 2016 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 197×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LBPS 4D pharma PLC Sponsored ADR compare | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| VERU Veru Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| SGMOQ Sangamo Therapeutics, Inc. compare | n/m |
| CELU Celularity, Inc. compare | n/m |
| GRCE Grace Therapeutics, Inc. | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| TIL Instil Bio, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)